AAPL339.50-3.44 (-1.00%) ▼|ABBV289.08+6.40 (+2.26%) ▲|ABT102.45-1.61 (-1.55%) ▼|ACN239.12+2.19 (+0.92%) ▲|ADBE256.73+9.64 (+3.90%) ▲|AMAT404.98-8.13 (-1.97%) ▼|AMD534.74-3.31 (-0.62%) ▼|AMGN438.94+14.00 (+3.29%) ▲|AMT183.56+0.53 (+0.29%) ▲|AMZN262.63+0.18 (+0.07%) ▲|AVGO334.37-0.22 (-0.07%) ▼|AXP318.34+1.93 (+0.61%) ▲|BA190.47-0.95 (-0.50%) ▼|BAC50.64+0.25 (+0.50%) ▲|BKNG163.92+1.32 (+0.81%) ▲|BLK1,128.68+4.08 (+0.36%) ▲|BMY61.68+2.85 (+4.84%) ▲|BNY144.25+1.81 (+1.27%) ▲|BRK-B539.82+7.59 (+1.43%) ▲|C122.51+0.82 (+0.67%) ▲|CAT725.24-0.55 (-0.08%) ▼|CL94.54+1.68 (+1.81%) ▲|CMCSA22.36+0.46 (+2.10%) ▲|COF201.56+1.73 (+0.87%) ▲|COP145.95+0.71 (+0.49%) ▲|COST994.61-0.92 (-0.09%) ▼|CRM242.43-0.02 (-0.01%) ▼|CSCO106.71+0.21 (+0.20%) ▲|CVS94.75+2.07 (+2.23%) ▲|CVX225.71+1.34 (+0.60%) ▲|DE632.20+5.20 (+0.83%) ▲|DHR224.24-0.19 (-0.08%) ▼|DIS111.67+2.08 (+1.90%) ▲|DUK121.33+2.06 (+1.73%) ▲|EMR160.46-0.08 (-0.05%) ▼|FDX298.76+4.98 (+1.70%) ▲|GD344.44+3.01 (+0.88%) ▲|GE299.87-11.41 (-3.67%) ▼|GEV890.33-18.11 (-1.99%) ▼|GILD156.51+3.44 (+2.25%) ▲|GM77.09-5.66 (-6.84%) ▼|GOOG336.40-3.76 (-1.11%) ▼|GOOGL340.28-3.91 (-1.13%) ▼|GS884.81+9.03 (+1.03%) ▲|HD315.11+5.23 (+1.69%) ▲|HON213.32+3.34 (+1.59%) ▲|IBM241.92+5.53 (+2.34%) ▲|INTC91.69-0.34 (-0.37%) ▼|INTU335.29+9.67 (+2.97%) ▲|ISRG438.00+4.82 (+1.11%) ▲|JNJ259.36+5.57 (+2.19%) ▲|JPM335.26+1.73 (+0.52%) ▲|KO93.49+0.07 (+0.07%) ▲|LIN501.89-1.55 (-0.31%) ▼|LLY1,283.66+43.32 (+3.49%) ▲|LMT548.71+0.48 (+0.09%) ▲|LOW198.53+2.61 (+1.33%) ▲|LRCX263.45-8.75 (-3.21%) ▼|MA620.42+4.02 (+0.65%) ▲|MCD246.52+3.85 (+1.59%) ▲|MDLZ63.99+0.65 (+1.03%) ▲|MDT94.63+1.86 (+2.01%) ▲|META694.25-11.19 (-1.59%) ▼|MMM171.37+9.36 (+5.78%) ▲|MO74.64+0.55 (+0.74%) ▲|MRK148.30+4.67 (+3.25%) ▲|MS180.40+1.93 (+1.08%) ▲|MSFT531.87-1.65 (-0.31%) ▼|MU896.07-8.83 (-0.98%) ▼|NEE78.86+0.69 (+0.88%) ▲|NFLX68.69-1.16 (-1.66%) ▼|NKE37.88+0.67 (+1.80%) ▲|NOW149.54+4.18 (+2.88%) ▲|NVDA216.47-0.62 (-0.29%) ▼|ORCL131.14+1.55 (+1.20%) ▲|PEP134.02+0.45 (+0.34%) ▲|PFE30.11+0.67 (+2.28%) ▲|PG159.32+1.63 (+1.03%) ▲|PLTR192.60-1.55 (-0.80%) ▼|PM199.90-1.15 (-0.57%) ▼|QCOM175.71+2.18 (+1.26%) ▲|RTX193.34+1.23 (+0.64%) ▲|SBUX99.37+1.50 (+1.53%) ▲|SCHW90.89+1.31 (+1.46%) ▲|SO90.71+1.44 (+1.61%) ▲|SPG206.99+4.50 (+2.22%) ▲|T23.42+0.22 (+0.95%) ▲|TMO687.37+7.99 (+1.18%) ▲|TMUS157.75+1.66 (+1.06%) ▲|TSLA373.71+5.65 (+1.54%) ▲|TXN277.78+1.63 (+0.59%) ▲|UBER68.94-1.02 (-1.46%) ▼|UNH419.26+12.38 (+3.04%) ▲|UNP287.61+0.60 (+0.21%) ▲|UPS98.52+1.06 (+1.09%) ▲|USB59.09+1.24 (+2.14%) ▲|V406.57+3.65 (+0.91%) ▲|VZ44.54+0.39 (+0.88%) ▲|WFC82.20+0.40 (+0.49%) ▲|WMT117.85-0.85 (-0.72%) ▼|XOM177.86-0.42 (-0.24%) ▼|AAPL339.50-3.44 (-1.00%) ▼|ABBV289.08+6.40 (+2.26%) ▲|ABT102.45-1.61 (-1.55%) ▼|ACN239.12+2.19 (+0.92%) ▲|ADBE256.73+9.64 (+3.90%) ▲|AMAT404.98-8.13 (-1.97%) ▼|AMD534.74-3.31 (-0.62%) ▼|AMGN438.94+14.00 (+3.29%) ▲|AMT183.56+0.53 (+0.29%) ▲|AMZN262.63+0.18 (+0.07%) ▲|AVGO334.37-0.22 (-0.07%) ▼|AXP318.34+1.93 (+0.61%) ▲|BA190.47-0.95 (-0.50%) ▼|BAC50.64+0.25 (+0.50%) ▲|BKNG163.92+1.32 (+0.81%) ▲|BLK1,128.68+4.08 (+0.36%) ▲|BMY61.68+2.85 (+4.84%) ▲|BNY144.25+1.81 (+1.27%) ▲|BRK-B539.82+7.59 (+1.43%) ▲|C122.51+0.82 (+0.67%) ▲|CAT725.24-0.55 (-0.08%) ▼|CL94.54+1.68 (+1.81%) ▲|CMCSA22.36+0.46 (+2.10%) ▲|COF201.56+1.73 (+0.87%) ▲|COP145.95+0.71 (+0.49%) ▲|COST994.61-0.92 (-0.09%) ▼|CRM242.43-0.02 (-0.01%) ▼|CSCO106.71+0.21 (+0.20%) ▲|CVS94.75+2.07 (+2.23%) ▲|CVX225.71+1.34 (+0.60%) ▲|DE632.20+5.20 (+0.83%) ▲|DHR224.24-0.19 (-0.08%) ▼|DIS111.67+2.08 (+1.90%) ▲|DUK121.33+2.06 (+1.73%) ▲|EMR160.46-0.08 (-0.05%) ▼|FDX298.76+4.98 (+1.70%) ▲|GD344.44+3.01 (+0.88%) ▲|GE299.87-11.41 (-3.67%) ▼|GEV890.33-18.11 (-1.99%) ▼|GILD156.51+3.44 (+2.25%) ▲|GM77.09-5.66 (-6.84%) ▼|GOOG336.40-3.76 (-1.11%) ▼|GOOGL340.28-3.91 (-1.13%) ▼|GS884.81+9.03 (+1.03%) ▲|HD315.11+5.23 (+1.69%) ▲|HON213.32+3.34 (+1.59%) ▲|IBM241.92+5.53 (+2.34%) ▲|INTC91.69-0.34 (-0.37%) ▼|INTU335.29+9.67 (+2.97%) ▲|ISRG438.00+4.82 (+1.11%) ▲|JNJ259.36+5.57 (+2.19%) ▲|JPM335.26+1.73 (+0.52%) ▲|KO93.49+0.07 (+0.07%) ▲|LIN501.89-1.55 (-0.31%) ▼|LLY1,283.66+43.32 (+3.49%) ▲|LMT548.71+0.48 (+0.09%) ▲|LOW198.53+2.61 (+1.33%) ▲|LRCX263.45-8.75 (-3.21%) ▼|MA620.42+4.02 (+0.65%) ▲|MCD246.52+3.85 (+1.59%) ▲|MDLZ63.99+0.65 (+1.03%) ▲|MDT94.63+1.86 (+2.01%) ▲|META694.25-11.19 (-1.59%) ▼|MMM171.37+9.36 (+5.78%) ▲|MO74.64+0.55 (+0.74%) ▲|MRK148.30+4.67 (+3.25%) ▲|MS180.40+1.93 (+1.08%) ▲|MSFT531.87-1.65 (-0.31%) ▼|MU896.07-8.83 (-0.98%) ▼|NEE78.86+0.69 (+0.88%) ▲|NFLX68.69-1.16 (-1.66%) ▼|NKE37.88+0.67 (+1.80%) ▲|NOW149.54+4.18 (+2.88%) ▲|NVDA216.47-0.62 (-0.29%) ▼|ORCL131.14+1.55 (+1.20%) ▲|PEP134.02+0.45 (+0.34%) ▲|PFE30.11+0.67 (+2.28%) ▲|PG159.32+1.63 (+1.03%) ▲|PLTR192.60-1.55 (-0.80%) ▼|PM199.90-1.15 (-0.57%) ▼|QCOM175.71+2.18 (+1.26%) ▲|RTX193.34+1.23 (+0.64%) ▲|SBUX99.37+1.50 (+1.53%) ▲|SCHW90.89+1.31 (+1.46%) ▲|SO90.71+1.44 (+1.61%) ▲|SPG206.99+4.50 (+2.22%) ▲|T23.42+0.22 (+0.95%) ▲|TMO687.37+7.99 (+1.18%) ▲|TMUS157.75+1.66 (+1.06%) ▲|TSLA373.71+5.65 (+1.54%) ▲|TXN277.78+1.63 (+0.59%) ▲|UBER68.94-1.02 (-1.46%) ▼|UNH419.26+12.38 (+3.04%) ▲|UNP287.61+0.60 (+0.21%) ▲|UPS98.52+1.06 (+1.09%) ▲|USB59.09+1.24 (+2.14%) ▲|V406.57+3.65 (+0.91%) ▲|VZ44.54+0.39 (+0.88%) ▲|WFC82.20+0.40 (+0.49%) ▲|WMT117.85-0.85 (-0.72%) ▼|XOM177.86-0.42 (-0.24%) ▼|
10.8 C
New York
Wednesday, October 21, 2026

Tag: blood vessels

newsFORsourcecompanycontentinformation1releasesmarket

Sun Pharma Announces UNLOXCYT® (cosibelimab-ipdl) Has Received a Category 2A Preferred Designation in the Updated NCCN Guidelines for Locally Advanced Cutaneous Squamous Cell Carcinoma...

MUMBAI, India and PRINCETON, N.J., Oct. 20, 2026 /PRNewswire/ -- Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715 (together...

Eisai Deepens Its Oncology Evidence Base at ESMO Congress 2026

Findings from the Phase 3 LITESPARK-011 and LITESPARK-012 studies reflect continued research into LENVIMA® (lenvatinib)-based combination regimens for patients with advanced renal cell carcinomaExploratory...

Par Health Issues Voluntary Nationwide Recall of Argatroban Injection Due to the Presence of Particulate Matter

ROCHESTER, Mich., Oct. 13, 2026 /PRNewswire/ -- Par Health is recalling 22 lots of Argatroban Injection 250 mg/2.5 mL (100 mg/mL) to the hospital/user...

Par Health Issues Voluntary Nationwide Recall of Two Lots of Brevital® Sodium 500 mg/vial CIV (Methohexital Sodium for Injection, USP) Due to the Presence...

ROCHESTER, Mich., Oct. 8, 2026 /PRNewswire/ -- Par Health is voluntarily recalling two lots of Brevital® Sodium 500 mg/vial CIV (Methohexital Sodium for Injection,...

Halloween scares should be spooky, not painful

Orthopaedic surgeons share simple tips to prevent falls, pumpkin-carving injuries and other Halloween mishapsROSEMONT, Ill., Oct. 8, 2026 /PRNewswire/ -- Halloween should be memorable...

Dentistry Expert Dr. Eric J. Smith Explains Broken Tooth Treatment Options in HelloNation

The Article Reviews How Dentists Evaluate Tooth Fractures and Decide Whether Repair or Extraction Offers a Stable Long-Term ResultLYNCHBURG, Va., Sept. 28, 2026 /PRNewswire/...

London Specialist Dentists Announce the Use of Ozone Therapy in Periodontal Treatment and Dental Implants

LONDON, June 04, 2026 (GLOBE NEWSWIRE) -- London Specialist Dentists has announced the use of medical-grade Ozone Therapy as part of its advanced approach to periodontal treatment, dental implant care, and minimally invasive gum therapy.

HelloNation Article Explains Protecting Eyes From Kentucky Allergies Featuring Optometry Expert Dr. Kimberly Arnett

The article clarifies how to distinguish allergy symptoms from infections and outlines steps to reduce irritation and protect eye health.FLORENCE, Ky., June 2, 2026...

Galvanize Announces First Patient Enrolled in the PROPEL Registry Evaluating Aliya® Pulsed Electric Field Ablation for Soft Tissue Lesions

Multicenter Registry Launches to Assess Real-World Outcomes and Clinical Integration of Nonthermal Aliya PEF Ablation REDWOOD CITY, Calif., Aug. 15, 2025 /PRNewswire/ -- Galvanize Therapeutics...

Precigen Announces Full FDA Approval of PAPZIMEOS (zopapogene imadenovec-drba), the First and Only Approved Therapy for the Treatment of Adults with Recurrent Respiratory Papillomatosis

PAPZIMEOS approval marks a historic milestone for the RRP patient community as the first and only FDA-approved therapy for the treatment of adults with...

Emmaus Life Sciences Reports Quarterly Financial Results

TORRANCE, Calif., Aug. 14, 2025 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQB: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell...

Roche’s Susvimo maintains vision over five years with two refills per year in people with neovascular age-related macular degeneration (nAMD)

Basel, 01 August 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new, five-year efficacy, safety and durability data from the Phase III Portal study, a long-term extension of the Phase III Archway study, of Susvimo® (ranibizumab injection) for the treatment of people with nAMD.1 Results show that Susvimo’s immediate and predictable durability was sustained over five years, with approximately 95% of people receiving treatment every six months requiring no supplemental treatment before each refill. The data were presented at the American Society of Retina Specialists (ASRS) 2025 Annual Meeting in Long Beach, California, United States.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsBlood vessels

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers